News

Lonza strikes global licensing deal with China’s CMS for brain-targeting drug tech

The deal targets one of the biggest hurdles in neurological drug development

  • By IPP Bureau | November 17, 2026
Lonza has struck a global exclusive licensing agreement with China Medical System Holdings Limited (CMS) to deploy its proprietary brain-delivery technology in the development of up to two products targeting neurodegenerative diseases.
 
Under the agreement, CMS will gain exclusive rights to Lonza’s NeuroPortal transferrin receptor 1 (TfR1) technology for the agreed product targets, marking a significant step in the commercial development of the platform.
 
Hong Kong-headquartered CMS is a pharmaceutical company focused on developing and commercializing specialty medicines, including treatments for central nervous system (CNS) disorders.
 
The deal targets one of the biggest hurdles in neurological drug development: getting medicines across the blood-brain barrier (BBB), the body's natural protective shield that prevents many therapeutic molecules from reaching the brain.
 
Lonza’s NeuroPortal TfR1 technology is designed to address this challenge by offering different binding variants that allow drug developers to fine-tune receptor engagement, transport across the blood-brain barrier and exposure within the brain.
 
In preclinical studies, the technology outperformed a leading industry benchmark both as an immunoglobulin G (IgG) fusion and when combined with Lonza’s GlycoConnect platform.
 
The technology, backed by Lonza’s capabilities in protein expression, bioconjugation and developability, offers pharmaceutical developers multiple approaches to designing and evaluating drug-delivery strategies for CNS treatments.
 
Under the financial terms, Lonza will receive an upfront payment, development and commercial milestone payments, as well as royalties on net sales. The company will retain the ability to license NeuroPortal TfR1 technology for other therapeutic programmes beyond the targets covered by the CMS agreement.
 
Peter Droc, Head of Licensing, Lonza, commented: “NeuroPortal TfR1 technology is designed to help optimize delivery of therapeutics to the brain, and gives developers flexibility to explore genetic fusion or bioconjugation approaches, tailoring the delivery strategy to the needs of their therapeutic molecule. 
 
"Delivering therapeutic molecules that can cross the blood-brain barrier remains a critical challenge in the development of treatments for neurodegenerative diseases. In selecting this platform, CMS is marking an important step in the commercial development of this technology.”

Upcoming E-conference

Other Related stories

Startup

Digitization

Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
(L-R) Manoj Kumar Panicker, General Manager, South Asia, Cytiva and Dr. Sanjib Banerjee, Chief Operating Officer (Biopharma Services), Veeda Lifesciences.